These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 36153949)

  • 1. Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects.
    Zhang Y; Yang M; Wu X; Deng F; Yin X; Ma R; Shi L
    ACS Appl Mater Interfaces; 2022 Oct; 14(39):44211-44221. PubMed ID: 36153949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanochaperones Mediated Delivery of Insulin.
    Li C; Liu X; Zhang Y; Lv J; Huang F; Wu G; Liu Y; Ma R; An Y; Shi L
    Nano Lett; 2020 Mar; 20(3):1755-1765. PubMed ID: 32069419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-temperature Responsive Hydrogel-Mediated Delivery of Exendin-4 Encapsulated Chitosan Nanospheres for Sustained Therapeutic Efficacy in Type 2 Diabetes Mellitus.
    Trinh TA; Le TMD; Nguyen HT; Nguyen TL; Kim J; Huynh DP; Lee DS
    Macromol Biosci; 2023 Nov; 23(11):e2300221. PubMed ID: 37365122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Albumin-binding tag derived Exendin-4 analogue for treating hyperglycemia and diabetic complications.
    Xu S; Wang F; Li H; Wang Y; Fang D
    Bioengineered; 2022 Mar; 13(3):4621-4633. PubMed ID: 34696658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.
    Zhao SJ; Wang DH; Li YW; Han L; Xiao X; Ma M; Wan DC; Hong A; Ma Y
    Int J Nanomedicine; 2017; 12():2143-2160. PubMed ID: 28356733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy.
    Chen W; Wang G; Yung BC; Liu G; Qian Z; Chen X
    ACS Nano; 2017 May; 11(5):5062-5069. PubMed ID: 28437610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and performance of exendin-4-loaded chitosan-PLGA microspheres for enhancing implant osseointegration in type 2 diabetic rats.
    Shi S; Song S; Liu X; Zhao G; Ding F; Zhao W; Zhang S; Song Y; Ma W
    Drug Deliv; 2022 Dec; 29(1):548-560. PubMed ID: 35156499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.
    Nielsen LL; Young AA; Parkes DG
    Regul Pept; 2004 Feb; 117(2):77-88. PubMed ID: 14700743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes.
    Tanday N; English A; Lafferty RA; Flatt PR; Irwin N
    Front Endocrinol (Lausanne); 2021; 12():674704. PubMed ID: 34054734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.
    Candeias E; Sebastião I; Cardoso S; Carvalho C; Santos MS; Oliveira CR; Moreira PI; Duarte AI
    Mol Neurobiol; 2018 May; 55(5):4030-4050. PubMed ID: 28573460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamatergic Alterations in STZ-Induced Diabetic Rats Are Reversed by Exendin-4.
    Zanotto C; Hansen F; Galland F; Batassini C; Federhen BC; da Silva VF; Leite MC; Nardin P; Gonçalves CA
    Mol Neurobiol; 2019 May; 56(5):3538-3551. PubMed ID: 30145785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thermo-reversible injectable gel based on enzymatically-chopped low molecular weight methylcellulose for exenatide and FGF 21 delivery to treat types 1 and 2 diabetes.
    Kim JK; Yoo C; Cha YH; Kim YH
    J Control Release; 2014 Nov; 194():316-22. PubMed ID: 25245775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway.
    Wei H; Bu R; Yang Q; Jia J; Li T; Wang Q; Chen Y
    J Diabetes Res; 2019; 2019():8905917. PubMed ID: 31886288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redox-active injectable gel using polyion complex to achieve sustained release of exenatide and enhance therapeutic efficacy for the treatment of type 2 diabetes.
    Ishii S; Sakaue S; Nagasaki Y
    J Biomed Mater Res A; 2019 May; 107(5):1107-1113. PubMed ID: 30720240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pH-Triggered Self-Unpacking Capsule Containing Zwitterionic Hydrogel-Coated MOF Nanoparticles for Efficient Oral Exendin-4 Delivery.
    Zhou Y; Chen Z; Zhao D; Li D; He C; Chen X
    Adv Mater; 2021 Aug; 33(32):e2102044. PubMed ID: 34216408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained Release of Exendin 4 Using Injectable and Ionic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus.
    Seo BB; Park MR; Song SC
    ACS Appl Mater Interfaces; 2019 May; 11(17):15201-15211. PubMed ID: 30945843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-diabetic properties of a non-conventional radical scavenger, as compared to pioglitazone and exendin-4, in streptozotocin-nicotinamide diabetic mice.
    Novelli M; Canistro D; Martano M; Funel N; Sapone A; Melega S; Masini M; De Tata V; Pippa A; Vecoli C; Campani D; De Siena R; Soleti A; Paolini M; Masiello P
    Eur J Pharmacol; 2014 Apr; 729():37-44. PubMed ID: 24530416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nitrilotriacetic Acid-Functionalized Glucose-Responsive Complex Micelles for the Efficient Encapsulation and Self-Regulated Release of Insulin.
    Li C; Huang F; Liu Y; Lv J; Wu G; Liu Y; Ma R; An Y; Shi L
    Langmuir; 2018 Oct; 34(40):12116-12125. PubMed ID: 30212220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Intracellular Delivery of siRNA by Controlling ATP-Responsivity of Phenylboronic Acid-Functionalized Polyion Complex Micelles.
    Naito M; Yoshinaga N; Ishii T; Matsumoto A; Miyahara Y; Miyata K; Kataoka K
    Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 29250901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
    Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
    Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.